Processa Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Processa Pharmaceuticals, Inc. (PCSA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 1.61 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 1.62M shares, a 1954.82% increase year-over-year.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 78.80K shares, a 95.78% decline year-over-year.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 2.02M shares, a 596.32% increase year-over-year.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-06-30 was 1.88M shares, a 637.69% increase year-over-year.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 1.64M shares, a 1932.08% increase from fiscal 2024.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 80.54K shares, a 72.82% decline from fiscal 2023.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 296.33K shares, a 129.81% increase from fiscal 2022.
- Processa Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 128.94K shares, a 84.32% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 1.61M shares 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | 1.62M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 1.64M shares 10-K · filed 2026-03-18 | |||||||
| 2025-09-30 | 40.09M shares 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | 1.22M shares 10-Q · filed 2026-08-14 | 30.55M shares 10-Q · filed 2025-08-07 | ||||||
| 2025-03-31 | 78.80K shares 10-Q · filed 2026-05-07 | 1.97M shares 10-Q · filed 2025-05-08 | ||||||
| 2024-12-31 | 80.54K shares 10-K · filed 2026-03-18 | 2.01M shares 10-K · filed 2025-03-20 | ||||||
| 2024-09-30 | 2.02M shares 10-Q · filed 2024-10-30 | 2.02M shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 1.88M shares 10-Q · filed 2024-08-13 | 1.88M shares 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | 1.87M shares 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | 296.33K shares 10-K · filed 2025-03-20 | |||||||
| 2023-09-30 | 289.94K shares 10-Q · filed 2024-10-30 | 289.94K shares 10-Q · filed 2024-10-30 | 5.80M shares 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | 254.31K shares 10-Q · filed 2024-08-13 | 5.09M shares 10-Q · filed 2023-08-10 | 254.31K shares 10-Q · filed 2024-08-13 | 5.09M shares 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | 236.50K shares 10-Q · filed 2024-05-10 | 4.73M shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 128.94K shares 10-K · filed 2024-03-29 | 2.58M shares 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | 2.76M shares 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | 1.97M shares 10-Q · filed 2023-08-10 | 1.97M shares 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 795.34K shares 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 822.43K shares 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | 844.39K shares 10-Q · filed 2022-11-08 | 844.39K shares 10-Q · filed 2021-11-12 | ||||||
| 2021-06-30 | 709.95K shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 989.53K shares 10-Q · filed 2022-05-12 | 1.02M shares 10-Q · filed 2021-05-13 | ||||||
| 2020-12-31 | 816.51K shares 10-K · filed 2022-03-30 | 816.51K shares 10-K · filed 2021-03-25 | ||||||
| 2020-09-30 | 1.26M shares 10-Q · filed 2021-11-12 | 1.15M shares 10-Q · filed 2020-11-12 | ||||||
| 2020-06-30 | 797.96K shares 10-Q · filed 2021-08-12 | 740.90K shares 10-Q · filed 2020-08-05 | ||||||
| 2020-03-31 | 762.16K shares 10-Q · filed 2021-05-13 | 782.92K shares 10-Q · filed 2020-05-15 | ||||||
| 2019-12-31 | 780.39K shares 10-K · filed 2021-03-25 | 715.45K shares 10-K · filed 2020-03-06 | ||||||
| 2019-09-30 | 662.44K shares 10-Q · filed 2020-11-12 | |||||||
| 2019-06-30 | 719.08K shares 10-Q · filed 2020-08-05 | |||||||
| 2019-03-31 | 660.51K shares 10-Q · filed 2020-05-15 | |||||||
| 2018-12-31 | 588.59K shares 10-K · filed 2020-03-06 | 3.90M shares 10-K · filed 2019-03-28 | ||||||
| 2017-12-31 | 1.26M shares 10-K/A · filed 2019-04-08 | |||||||
| 2015-03-31 | 3.69M shares 10-Q · filed 2015-05-15 | |||||||
| 2014-12-31 | 3.67M shares 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |